Hims & Hers Health Inc
HIMSToday
-3.52%
5 Days
-8.42%
1 Month
-2.92%
6 Months
-35.29%
Year to Date
+48.47%
1 Year
+19.59%
TradingKey Stock Score of Hims & Hers Health Inc
Currency: USD Updated: 2025-12-12Key Insights
Hims & Hers Health Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 44/78 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 46.32.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Hims & Hers Health Inc's Score
Support & Resistance
Score Analysis
Analyst Rating
Hims & Hers Health Inc Highlights
Hims & Hers Health Inc News
Hims & Hers Health Inc (HIMS): The Opportunity is still Strong and Potent
TradingKey - Despite the whole controversy with NVO, we believe HIMS is able to achieve 6 million subscribers and $6 billion of revenue by 2030, due to the large opportunity of growth for the telehealth industry, early investments in logistics capabilities and ability to upsell their patients.
US FTC investigating Hims & Hers over advertising and cancellation practices, Bloomberg News reports
Aug 14 (Reuters) - The U.S. Federal Trade Commission is probing complaints about telehealth platform Hims & Hers HIMS.N regarding its advertising and cancellation practices, according to a Bloomberg News report citing people familiar with the matter.
Hims & Hers: A Game-Changer in Telehealth or Just Another Fad?
Explore the exciting world of Hims & Hers (NYSE: HIMS) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
“King of Knockoff Weight-Loss Drugs” Still Struggling — Hims & Hers Misses Revenue, Stock Drops 12% After Hours
TradingKey - Despite a 73% year-on-year revenue increase in Q2 2025 that highlights the growth potential of the digital health sector, Hims & Hers (HIMS), a high-profile player in the AI-driven telehealth space, continues to face mounting legal and operational challenges. The negative impact on its
Novo Nordisk Terminates Weight-Loss Drug Partnership with Hims&Hers – NVO Drops 7%, HIMS Plummets 25%
TradingKey - Just two months into their weight-loss drug partnership, Novo Nordisk (NVO) announced on Monday, June 23, that it is terminating its collaboration with telehealth company Hims&Hers (HIMS). The move sent shockwaves through the market, with shares of the so-called "AI + healthcare" growth
HIMS: When Overvaluation Isn’t What It Seems
TradingKey - The stock market is sending mixed messages about Hims & Hers Health (HIMS). On the plus side, the shares are trading higher by approximately 16% for the day, continuing a red-hot YTD run; on the other, the stock looks overvalued on paper with GAAP P/E and EV/EBITDA multiples several tim
Financial Indicators
EPS
Total revenue
Hims & Hers Health Inc Info
FAQs
What is the current price of Hims & Hers Health Inc (HIMS)?
What is the symbol of Hims & Hers Health Inc?
What is the 52-week high of Hims & Hers Health Inc?
What is the 52-week low of Hims & Hers Health Inc?
What is the market capitalization of Hims & Hers Health Inc?
What is the net income of Hims & Hers Health Inc?
Is Hims & Hers Health Inc (HIMS) currently rated as Buy, Hold, or Sell?
What is the Earnings Per Share (EPS TTM) of Hims & Hers Health Inc (HIMS)?
Related Instruments
Popular Symbols
